NZ625944A - Antibodies against cd38 for treatment of multiple myeloma - Google Patents

Antibodies against cd38 for treatment of multiple myeloma

Info

Publication number
NZ625944A
NZ625944A NZ625944A NZ62594406A NZ625944A NZ 625944 A NZ625944 A NZ 625944A NZ 625944 A NZ625944 A NZ 625944A NZ 62594406 A NZ62594406 A NZ 62594406A NZ 625944 A NZ625944 A NZ 625944A
Authority
NZ
New Zealand
Prior art keywords
seq
human
treatment
antibodies against
multiple myeloma
Prior art date
Application number
NZ625944A
Other languages
English (en)
Inventor
Paul Parren
Yvo Graus
Judith Oprins
Michel De Weers
Martine Van Vugt
Jan Van De Winkel
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of NZ625944A publication Critical patent/NZ625944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ625944A 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma NZ625944A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20
NZ600059A NZ600059A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
NZ625944A true NZ625944A (en) 2016-01-29

Family

ID=50644285

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ625944A NZ625944A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma
NZ600059A NZ600059A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600059A NZ600059A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Country Status (12)

Country Link
KR (1) KR20140033240A (OSRAM)
BE (1) BE2017C062I2 (OSRAM)
DK (1) DK1866338T3 (OSRAM)
ES (2) ES2644982T3 (OSRAM)
HU (2) HUE030783T2 (OSRAM)
LT (2) LT1866338T (OSRAM)
NZ (2) NZ625944A (OSRAM)
PL (1) PL1866338T3 (OSRAM)
PT (2) PT2567976T (OSRAM)
RS (1) RS55442B1 (OSRAM)
SG (1) SG10201610317VA (OSRAM)
UA (2) UA116520C2 (OSRAM)

Also Published As

Publication number Publication date
RS55442B1 (sr) 2017-04-28
LT1866338T (lt) 2017-01-25
ES2644982T3 (es) 2017-12-01
SG10201610317VA (en) 2017-02-27
PT2567976T (pt) 2017-10-19
UA116520C2 (uk) 2018-04-10
DK1866338T3 (da) 2017-01-02
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
PT1866338T (pt) 2016-12-14
UA98756C2 (ru) 2012-06-25
ES2606762T3 (es) 2017-03-27
PL1866338T3 (pl) 2017-04-28
KR20140033240A (ko) 2014-03-17
BE2017C062I2 (OSRAM) 2025-12-03
LT2567976T (lt) 2017-12-11
NZ600059A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ716587A (en) Antibodies specific for claudin 6 (cldn6)
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
CO6450613A2 (es) Uso de anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
NZ595825A (en) Antibody containing igg2 having amino acid mutation introduced therein
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
UA101487C2 (en) Humanized b-ly1 antibody formulation
MX2009003126A (es) Agente para prevenir/tratar el cancer.
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
MX2008008298A (es) Sal de sulfato de hidrogeno novedosa.
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
TW200727791A (en) Materials and methods for improving livestock productivity
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
NZ595863A (en) Antibodies to egfl7 and methods for their use
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 23 MAR 2019 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS

Effective date: 20160504

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2020 BY CPA GLOBAL

Effective date: 20190208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2021 BY CPA GLOBAL

Effective date: 20200206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2022 BY CPA GLOBAL

Effective date: 20210204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2023 BY CPA GLOBAL

Effective date: 20220204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2024 BY CPA GLOBAL

Effective date: 20230210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250206